Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Subtraction Normalized Aggregated Phagocytic Signal in Peripheral Blood of Breast Cancer Patients (SNAPS - Clinical Trial) A NextGen RNASeq Feasibility Study of a Blood-based Model for Early Cancer Detection and Surveillance

NCT05370300 is registered in ClinicalTrials.gov with Immunis.AI as lead sponsor.

NCT NCT05370300
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05370300 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Subtraction Normalized Aggregated Phagocytic Signal in Peripheral Blood of Breast Cancer Patients (SNAPS - Clinical Trial) A NextGen RNASeq Feasibility Study of a Blood-based Model for Early Cancer Detection and Surveillance
Lead sponsor
Immunis.AI
Phase
Observational
Overall status
Not yet recruiting
Start date
September 1, 2025
Completion date
December 31, 2027
Enrollment
500 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer female